Dr. Cecil Czerkinsky, a leading French immunologist, joins the International Vaccine Institute as the Deputy Director-General for Laboratory Sciences on September 1, bringing his ample vaccine research and development expertise to the Seoul-based international organization.
Czerkinsky, 52, has been serving as the Director of the Division of Mucosal Immunology and Vaccinology at INSERM (French National Institute of Health and Medical Research) since 1997, focusing on vaccine research and discovery of the basic mechanisms governing induction of immunity in mucosal organs.
Czerkinsky, a medical doctor, received doctoral degrees from the University of Nice in France, and the University of Gothenburg in Sweden, and served as Professor of Immunology at the two universities. He has more than 130 scientific peer-reviewed publications in basic, clinical immunology and vaccinology.
Czerkinsky invented the ELISPOT, a method for monitoring B and T lymphocyte immune responses in humans and animals, which is widely used in laboratories world-wide. Czerkinski also holds six patents, several of which have been licensed to companies.
He is also a co-founder of Syntello Vaccine Development AB, a Swedish biotechnology company dedicated to developing vaccines against sexually transmitted diseases such as AIDS and human papilloma virus, and Maxim Pharmaceuticals Inc., a U.S. biopharmaceutical firm devoted to the development of therapeutic drugs for cancer and liver diseases.
The IVI, which is the only international organization headquartered in Korea, operates laboratory research programs to develop new vaccines at its headquarters on the campus of Seoul National University, and translational research programs to accelerate the introduction of life-saving vaccines for the poor in 21 developing countries worldwide.